No profile data available.
Terns Pharmaceuticals, Inc. (TERN) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Foster City, United States, with about 59 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$96.21 million. Its market capitalization was $2.44 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
Terns Pharmaceuticals reported $0 in revenue for fiscal year 2025.
$2.44 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Viking Therapeutics, Inc. (VKTX), Prestige Consumer Healthcare Inc. (PBH), Beam Therapeutics Inc. (BEAM), Adma Biologics, Inc. (ADMA).